Evidence map›Paper›PMID 42606020›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.

Rongkang Li, Anguo Zhao, Qi Zhuang, Lei Peng, Rui Liang, Jiadong Zhao, Yang Liu, Dashi Deng, Peng Yu, Xiqi Peng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rongkang LiDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Anguo ZhaoDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Qi ZhuangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Lei PengDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.ORCID https://orcid.org/0009-0002-3171-3137
Rui LiangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.ORCID https://orcid.org/0009-0001-8292-4201
Jiadong ZhaoDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Yang LiuDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Dashi DengDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
Peng YuDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Xiqi PengDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.ORCID https://orcid.org/0000-0003-4421-5188
Shaohua ZhangDepartment of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.ORCID https://orcid.org/0000-0002-2396-6129
Song WuDepartment of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.

Funding

National Key Research and Development Program of China 2025YFF0515300National Key Research and Development Program of China 2025YFF0515304National Natural Science Foundation of China 82572292National Natural Science Foundation of China 92359202Project funded by China Postdoctoral Science Foundation 2024M762130Sanming Project of Medicine in Shenzhen SZSM202211009Sanming Project of Medicine in Shenzhen SZSM202411033Shenzhen Engineering Research Center XMHT20220104016Shenzhen Medical Research Fund A2502022Shenzhen Medical Research Fund A2503070Shenzhen Science and Technology Innovation Commission JCYJ20240813144023031Shenzhen Science and Technology Innovation Commission RCJC20200714114557005Shenzhen Science and Technology Program JCYJ20230807141009020Shenzhen Science and Technology Program QNXMC20250701091514019Shenzhen Science and Technology Program QNXMC20250701091517023Shenzhen Science and Technology Program SYSRD20250529113406008
6 · The paper itself

Abstract

Bladder cancer (BC) is a highly recurrent urinary malignancy for which current intravesical immunotherapy and chemotherapy are limited by insufficient efficacy, toxicity, excessive inflammation, and drug resistance. The probiotic Akkermansia muciniphila (AKK), known for its ability to modulate immune responses and suppress pathological inflammation, provides a promising immunomodulatory component to address these limitations. Here, an intravesical bacteria-based chemo-immunotherapeutic platform is developed by loading doxorubicin (DOX) onto pasteurized AKK modified with F127, yielding AKK-F127/DOX (AF/D). Compared with free DOX, AF/D more effectively inhibits bladder cancer cell proliferation, migration, and invasion, while inducing apoptosis, ferroptosis, immunogenic cell death, and suppressing the NF-κB inflammatory pathway. AF/D also promotes dendritic-cell maturation, pro-inflammatory cytokine secretion, M1-like macrophage polarization, antigen cross-presentation, and tumor-specific CD8

Indexed as

akkermansia muciniphilabladder cancerchemo‐immunotherapyferroptosisintravesical therapy

Identifiers

PMID42606020
PMCPMC13479586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.